Grail Stock Plunge Sparks Contrarian Investment Debate
Thursday / 05/21/2026, 00:36 EST
Grail shares fell sharply after a failed clinical trial, but some analysts see a 30% upside. The biotech firm's revenue is growing, yet FDA approval remains elusive.
